G49108TO
| Organisms | Evidence |
|---|---|
| Streptococcus pneumoniae | |
| Mus musculus (house mouse) | |
| Saccharomyces cerevisiae (brewer's yeast) | |
| Sus scrofa (pig) | |
| Rattus norvegicus (Norway rat) |
| Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
|---|---|---|---|---|---|---|
| B4GALT5 | (not applicable) |
|
[beta]-S-pNP |
|
[beta]-S-pNP | |
| B4GALT1 | UDP-Gal |
|
R |
|
R | |
| B4GALT2 | UDP-Gal |
|
Benzyl-[beta] |
|
Benzyl-[beta] | |
| B3GALT2 | UDP-Gal |
|
Lemieux |
|
Lemieux | |
| B3GALT5 | UDP-Gal |
|
R |
|
R |
| Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
|---|---|---|---|---|---|---|
| B4GALT5 | (not applicable) |
|
[beta]-S-pNP |
|
[beta]-S-pNP | |
| B4GALT4 | UDP-Gal |
|
[beta]-1-thio-p-Nitrophenyl |
|
[beta]-1-thio-p-Nitrophenyl | |
| B4GALT3 | UDP-Gal |
|
4-Me-lumbelyl-[beta] |
|
4-Me-lumbelyl-[beta] | |
| B4GALT4 | UDP-Gal |
|
[beta]-1-4-methyl-umbelliferyl |
|
[beta]-1-4-methyl-umbelliferyl | |
| B4GALT1 | UDP-Gal |
|
|
| Pathway Name | Organism |
|---|---|
| Antimicrobial peptides | Sus scrofa |
| Antimicrobial peptides | Rattus norvegicus |
| Antimicrobial peptides | Dictyostelium discoideum |
| Antimicrobial peptides | Bos taurus |
| Antimicrobial peptides | Canis familiaris |
| Antimicrobial peptides | Mus musculus |
| Antimicrobial peptides | Gallus gallus |
| Antimicrobial peptides | Homo sapiens |
| Antimicrobial peptides | Drosophila melanogaster |
| Antimicrobial peptides | Xenopus tropicalis |
RES 1b:b-dglc-HEX-1:5 2s:n-acetyl LIN 1:1d(2+1)2n
| PubMed ID | Title | First Author | Publication Date | Source |
|---|---|---|---|---|
| 36124412 | Hexosamine pathway activation improves memory but does not extend lifespan in mice | Allmeroth K | 2022 Sep 19 |
|
| 36115831 | Structural mechanism of tapasin-mediated MHC-I peptide loading in antigen presentation | Jiang J | 2022 Sep 17 |
|
| 35971553 | Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways | Zhao F | 2022 Sep 16 |
|
| 36103542 | Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response | Dickey TH | 2022 Sep 16 |
|
| 36109732 | A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode | Zhao D | 2022 Sep 15 |
|
| 36106687 | Crystal structure and sugar-binding ability of the C-terminal domain of N-acetylglucosaminyltransferase IV establish a new carbohydrate-binding module family | Oka N | 2022 Sep 15 |
|
| 36104594 | The value of injectable viscoelastic supplements for joints | Bowden DJ | 2022 Sep 14 |
|
| 36104770 | O-GlcNAcylation: an important post-translational modification and a potential therapeutic target for cancer therapy | Lu Q | 2022 Sep 14 |
|
| 35952670 | Allelic polymorphism controls autoreactivity and vaccine elicitation of human broadly neutralizing antibodies against influenza virus | Sangesland M | 2022 Sep 13 |
|
| 35977542 | Vaccination with a structure-based stabilized version of malarial antigen Pfs48/45 elicits ultra-potent transmission-blocking antibody responses | McLeod B | 2022 Sep 13 |
|
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.4.0
Last updated: December 8, 2025